dalfopristin/quinupristin (Synercid)
Jump to navigation
Jump to search
Indications
- bacterial infections due to susceptible organisms
FDA approved for treatment of life-threatening infections associated with:
- VREF bacteremia
- complicated skin & skin structure infections due to:
- Staphylococcus aureus (methicillin sensitive)
- Streptococcus pyogenes
- empiric treatment for fever of unknown origin[6]
Dosage
- 7.6 mg/kg IV every 8 hours
- 10-20 mg/kg/day divided every 12 hours
Pharmacokinetics
- 75% excreted in feces
- 20% excreted in urine
- elimination 1/2life is 1.3-1.5 hours
- no dosage adjustment needed for elderly[5]
Antimicrobial activity
Adverse effects
(fairly toxic)
Drug interactions
- inhibits cyt P450 3A4
- may increase levels of drugs metabolized by cyt P450 3A4
Mechanism of action
- acts on bacterial ribosome
- inhibits both early & late protein synthesis
More general terms
Components
References
- ↑ Micromedex vol 101
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Kaiser Permanente, Drug update 6/2000 & summer 2000
- ↑ Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 5.0 5.1 5.2 Norman, D, In: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
- ↑ 6.0 6.1 Deprecated Reference